Sandoz Names Board Ahead Of Novartis Spinoff
Preparatory Work Begins In June; Formal Constitution Of Board To Follow By Year End
As Sandoz moves closer to being spun off from parent company Novartis, the generics and biosimilars firm has revealed the structure and membership of its board under chair Gilbert Ghostine.
